Fertility and Sterility, 45(4), 575-577
The incidence of congenital anomalies in infants born to 382 women treated with P was noted. Only five anomalies occurred in the infants born to women who had taken P. This study supports the data of Rock et al. by demonstrating a similar low incidence of birth defects in a much larger series of patients who also took a much higher dosage of P. Similarly, because only 1 of 189 patients treated with both P and 17-OHP developed anomalies, the data supports the study by Katz et al., suggesting no increase in anomalies related to 17-OHP therapy.
Check, J. H., Rankin, A., & Teichman, M. (1986). The risk of fetal anomalies as a result of progesterone therapy during pregnancy. *Fertility and sterility*, *45*(4), 575-577. https://doi.org/10.1016/s0015-0282(16)49292-7
Check JH, Rankin A, Teichman M. The risk of fetal anomalies as a result of progesterone therapy during pregnancy. Fertil Steril. 1986;45(4):575-577. doi:10.1016/s0015-0282(16)49292-7
Check, J. H., et al. "The risk of fetal anomalies as a result of progesterone therapy during pregnancy." *Fertility and sterility*, vol. 45, no. 4, 1986, pp. 575-577.
17-alpha-Hydroxyprogesterone, Abnormalities, Drug-Induced/epidemiology, Abortion, Spontaneous/prevention & Control, Drug Therapy, Combination, Female, Humans, Hydroxyprogesterones/administration & Dosage/adverse Effects, Infant, Newborn, Injections, Intramuscular, Pregnancy, Pregnancy Trimester, First, Progesterone/administration & Dosage/adverse Effects, Retrospective Studies, Risk, Suppositories, Surveys and Questionnaires, Vagina, Hydroxyprogesterones, Suppositories, Progesterone, 17-alpha-Hydroxyprogesterone,